Genetic design, cell therapy manufacturing, viral vector drug substance and drug product — including targeted LVV for in vivo CAR-T — plus cell banking, technology transfer, and dedicated project teams, engineered to work together in the Bay Area.
Genetic circuit design and machine-learning sequence optimization, plus proprietary tools — cell-specific promoters, kill switches, targeting/detargeting molecules — and targeted LVV development for in vivo CAR-T.
End-to-end autologous & allogeneic GMP manufacturing across all cell types — T cells (CAR/TCR/γδ), NK, Tregs, iPSC, HSC, MSCs, macrophages, TILs & B cells — plus in vivo CAR-T. Multiple expansion platforms tuned to your modality.
GMP lentiviral & gamma-retroviral vector as drug substance or finished drug product — for ex vivo cell therapy and in vivo LVV therapies, including in vivo CAR-T. Adherent (2–20 L) and suspension GMP (50–200 L).
Engineering, Master, and Working cell bank generation — adherent & suspension platforms. Full characterization, qualified storage, scale-up as needed.
Knowledge transfer treated as a discipline, not a checkbox. Structured gap assessments, engineering runs, on-the-floor MSAT — development to GMP in ~7 months; commercial-to-commercial up to 24 months.
Dedicated PMO, transparent Gantt charts, cloud-based data exchange, routine technical and quality reviews. One accountable team across Genetic Design, PD, Manufacturing, AD, and QC.
